Trial Information

Summary: PHI-59 NCI #8057: Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction

You have been asked to participate in this research study because you have an advanced cancer and the standard drugs to treat your disease are no longer effective or there is no effective treatment available for your disease.  The purpose of this study is to find out the highest possible dose of the investigational drug vorinostat that can be given to subjects with advanced cancer and different degrees of liver function before unmanageable side effects are seen.  Other purposes of this research study will be to examine what side effects occur when the drug is given to subjects with different degrees of liver function, how much vorinostat is in the blood at specific times after it is received, and whether or not vorinostat is effective in treating various types of advanced cancer.  Your treatment on this study is expected to last for as long as your cancer is not growing and you are not having any unmanageable side effects.  After your treatment on this study is over, your medical condition will be followed on the study for 28 days.   

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:42:25 PM